AI assistant
DEXCOM INC — Director's Dealing 2024
Apr 10, 2024
30198_dirs_2024-04-10_715447b0-f1cb-4db9-b84d-8d5ff0f6a5d4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2024-04-08
Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-08 | Common Stock | S | 27272 | $137.9616 | Disposed | 306254 | Direct |
| 2024-04-08 | Common Stock | S | 22361 | $138.7079 | Disposed | 283893 | Direct |
Footnotes
F1: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $137.61 to $138.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.
F4: This transaction was executed in multiple trades at prices ranging from $138.385 to $139.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.